Back Home About Us

CROI 2017: Dual Antiretroviral Regimen Maintains Durable HIV Suppression after Switch

People who switched from standard antiretroviral therapy to a 2-drug regimen of dolutegravir (Tivicay) plus rilpivirine (Edurant) were able to maintain an undetectable viral load for 48 weeks in a pair of late-stage clinical trials, according to a late-breaking report at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

Golden Compass Program Launches at San Francisco General Hospital

The Golden Compass program is now open at Zuckerberg San Francisco General Hospital's Ward 86, offering one-stop shopping for HIV-positive people age 50 and older. The program, which started seeing patients this past fall, held its official launch party on February 3.

alt

Read more:

HIVandHepatitis.com 2016 Conference Coverage

Article listings by topic for HIVandHepatitis.com conference coverage in 2016, including the Conference on Retroviruses and Opportunistic Infections, EASL International Liver Congress, International AIDS Conference, and AASLD Liver Meeting.

alt

Read more:

Hope Overshadowed -- The National HIV PrEP Summit

The U.S. National HIV PrEP Summit, which took place in early December in San Francisco, was designed as an event of celebration and hope. Its structure, its speakers, even the way the plenary room was designed and the way the speakers dressed, all conveyed one message: we are all in this together, and pre-exposure prophylaxis (PrEP) really is the game-changer we have been looking for.

alt

Read more:

Top 10 HIV and Hepatitis Stories of 2016

Simplification and optimization of antiretroviral therapy for HIV, wider use of pre-exposure prophylaxis (PrEP), a growing appreciation that people with undetectable viral load do not transmit HIV, and an expanded armamentarium of treatments for hepatitis C were among the top HIV and viral hepatitis headlines this year. Here's a look back at some of our biggest news from 2016.

alt

Read more:

No New HIV Infections in Northern California Kaiser PrEP Program, but STI Rates Rising

No new HIV infections have been seen among nearly 1000 people who started Truvada for pre-exposure prophylaxis (PrEP) at Kaiser Permanente Northern California, according to a report in the December 15, 2016, Journal of Acquired Immune Deficiency Syndromes. The most recent analysis shows, however, that incidence of chlamydia and gonorrhea is high, suggesting that sexually transmitted infection (STI) testing may be needed quarterly rather than every 6 months.

alt

Read more:

Dolutegravir + Rilpivirine HIV Maintenance Regimen Looks Good in Phase 3 Studies

Switching to a 2-drug regimen of dolutegravir plus rilpivirine maintained viral suppression among people on successful 3- or 4-drug antiretroviral therapy (ART) in a pair of Phase 3 clinical trials, according to an announcement last week from ViiV Healthcare.

alt

Read more:

Study Shows Supervised Injection Facility Would Be Cost-Effective in San Francisco

Establishing a supervised consumption facility for people who inject drugs in San Francisco could reduce new HIV and hepatitis C virus (HCV) infections, decrease overdose deaths, and save millions of dollars, according to a mathematical modeling study recently published online in the Journal of Drug Issues.

alt

Read more:

U.K.'s Largest Sexual Health Clinic Saw 40% Drop in New HIV Diagnoses in 2016

The clinic at 56 Dean Street in Soho, central London, the largest sexual health clinic in the U.K., saw an unprecedented 40% drop in new HIV diagnoses this year. Another clinic, the Mortimer Market Centre a mile away from Dean Street, has seen an even bigger 50% fall.

alt

Read more: